Clinical Trials Browser

Enrolling by invitation × Neoplasm, Residual × 90 days × Clear all

NCT07537257 2026-04-17

VEN+IDAC vs IDAC in AML

Phase 2/3 Enrolling by invitation

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual